Almost All Hopes Dashed For Pfizer/Medivation's Dimebon
This article was originally published in The Pink Sheet Daily
Executive Summary
After a disastrous failure in Alzheimer's disease last year, Dimebon once again disappoints in a Phase III trial - this time in Huntington disease.